NCT00741234View on ClinicalTrials.gov

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Solid TumorsHematologic MalignanciesMyelodysplastic Syndrome
Interventions
DRUG

SB939

SB939 taken orally in a 4-week cycle.

DRUG

Azacitidine

Azacitidine taken orally with SB939 in a 4-week cycle

Trial Locations (5)

53792

University of Wisconsin-Madison, Madison

77030

MD Anderson Cancer Center, Houston

119074

National University Hospital, Singapore

160610

National Cancer Center, Singapore

169608

Singapore General Hospital, Singapore

All Listed Sponsors
lead

S*BIO

INDUSTRY

NCT00741234 - A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine | Biotech Hunter | Biotech Hunter